Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Medical Research Council Clinical Trials Unit, London, United Kingdom



Survival: 13.0 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs: Taxol
Country: United Kingdom
   
City/State/Province: London
   
Hospital: Medical Research Council Clinical Trials Unit
   
Journal: Link
   
Date: 11/2005

Description:
Patients: This Phase III study involved 705 women (median age 54) with advanced breast cancer with metastases in bone, liver, lung, lymph nodes, and other tissues. Ninety-five women had received prior adjuvant chemotherapy. The patients were randomly divided into two groups. Group B had 353 women (median age 54).

Treatment: For Group B, treatment consisted of two chemotherapeutic agents: epirubicin and paclitaxel.

Toxicity: 48% of Group B patients reported grade 3-4 toxicities, including alopecia, nausea/vomiting, infection, pain, mucositis, and neurotoxicity.

Results: For Group A (epirubicin and cyclophosphamide), the median overall survival was 14 months. For Group B (epirubicin and paclitaxel), the median overall survival was 13 months. The authors concluded, "The data demonstrate no additional advantage to using EP instead of EC as first-line chemotherapy for MBC in taxane-naive patients."

Support: The study was financially supported by Bristol-Myers Squibb and Pharmacia Upjohn. Bristol-Myers Squibb manufactures and/or markets Paclitaxel and Cyclophosphamide and Pharmacia Upjohn manufactures and/or markets Epirubicin.

Correspondence: Ruth Langley, MD

E-mail to a Friend Email Physician More Information